Funding sources
This work was made possible by research support from the National
Institute on Drug Abuse of the National Institutes of Health
36 L.-T. Wu et al. / Contemporary Clinical Trials 46 (2016) 30–38
(U10DA013727; UG1DA040317; HHSN271200522071C;
HHSN271201200017C, N01DA-12-2229; HHSN271201400028C,
N01DA-14-223), the Centers for Medicare and Medicaid Services
(1C1CMS331018), and the Bristol-Myers Squibb Foundation. LT Wu
also received support from the following NIH grants: R01MD007658,
R01DA019623, R01DA019901, and R33DA027503. The sponsoring
agencies have no further role in the study design and analysis, the writing
of the report, or the decision to submit the paper for publication. The
opinions expressed in this paper are solely those of the authors and do
not represent the official position of the U.S. government and the
Bristol-Myers Squibb Foundation.